Abstract
Addition of Ixazomib to an Rd Backbone Improves Clinical Benefit in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) with Non-Canonical NF-KB Activation — Results from the Tourmaline-MM1 Study
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have